Product category:
Contract research
News Release from: LGC | Subject: HyBeacons
Edited by the Laboratorytalk Editorial
Team on 01 September 2006
LGC wins first European patent for
HyBeacons
HyBeacon probes were developed at LGC in response to forensic and medical requirements to identify key genetic differences between individuals, or to distinguish micro-organisms
On July 25 2006, LGC's first patent application associated with its innovative HyBeacons technology was granted within the European patent territories LGC's David McDowell and David French, along with Professor Tom Brown of Southampton University, are the named inventors of the technology behind the patent entitled: 'Hybridisation beacon and method of rapid sequence detection and discrimination'
This article was originally published on Laboratorytalk on 10 Jun 2002 at 8.00am (UK)
Related stories
New FTMS for LGC
LGC selects £500k Bruker Daltonics Fourier transform instrument to expand its mass spectrometry capability for chemical and bio-molecules
Catalogue of abuse
Reference materials for clinical, forensic and toxicological analysis updated to include new matrix materials including drugs of abuse in saliva
HyBeacons are short DNA sequences that contain a fluorescent molecule attached within the heart of the sequence.
HyBeacons can be designed to act as probes to detect sections of DNA sequence with a genetic variation.
The central location of the fluorescent molecule within the probe has considerable advantages over previously invented probes that have such signalling chemistry placed at the end of the DNA probe.
Further reading
USP Standards 100 course comes to Europe
Seminars for pharmaceutical industry professionals in the use of USP-NF (United States Pharmacopoeia and National Formulary) standards in Runcorn, UK, and Luckenwalde, Germany
Practical training for measurement in the lab
Valid Analytical Measurement programme publishes new guides on CD-Rom designed to make achieving best laboratory practice easy for inexperienced staff
HyBeacon probes were developed at LGC in response to forensic and medical requirements to identify key genetic differences between individuals, or to distinguish micro-organisms and have unique characteristics that make them suitable for very rapid diagnostic and point-of-care applications.
To date, HyBeacon assays have been designed for use in medical genetic as well as infectious diagnostic testing.
Potential applications range from the ability to determine whether an individual will derive therapeutic value from certain prescribed drugs through to rapid confirmation of a suspected infection.
As a recent example LGC, in association with the Institute of Psychiatry at King's College London, has used its HyBeacons technology to enable the development of a pharmacogenetic screening service which can predict whether a patient with schizophrenia will respond positively to the antipsychotic drug clozapine.
Commenting on the news of the patent, David McDowell, life sciences business development manager at LGC, said: "We are absolutely delighted at the news of the new patent, which is LGC's first EU patent grant since privatisation.
"Furthermore, our patent application has now progressed to grant in both New Zealand and South Africa and is now under assessment by US, Canadian and Australian patent examiners.
"This is important recognition for HyBeacons and I am pleased to say that a number of in-house service applications and external licence deals are now in progress.
"A second patent is pending".
In 2004, LGC granted its first HyBeacons licence to Osmetech, for use in medical genetic test applications for analyte specific reagents that indicate inherited genetic traits.
Most recently LGC announced its participation in a research project, funded under the EPSRC Think Crime programme, looking at ways in which LGC's HyBeacons technology can be further developed for the specific requirements of forensic analysis.
• LGC: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
